Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study.
BACKGROUND AND AIM
It is unclear whether vedolizumab therapy can be discontinued in patients with inflammatory bowel disease [IBD] after achieving steroid-free clinical remission. The aim was to assess the risk of relapse after vedolizumab therapy was discontinued.


METHODS
This was a retrospective observational study, collecting data from 21 tertiary centres affiliated with the GETAID from January 2017 to April 2019. Consecutive patients with IBD, who were in steroid-free clinical remission for at least 3 months and were treated with vedolizumab for at least 6 months, were included at the time of vedolizumab discontinuation.


RESULTS
A total of 95 patients [58 with Crohn's disease] discontinued vedolizumab after a median duration of therapy of 17.5 [10.6-25.4] months. After a median follow-up period of 11.2 [5.8-17.7] months, 61 [64%] patients experienced disease relapse. The probabilities of relapse-free survival were 83%, 59%, and 36% at 6, 12, and 18 months, respectively. According to the multivariate analysis, a C-reactive protein level less than 5 mg/L at vedolizumab discontinuation (hazard ratio [HR] = 0.56, 95% confidence interval [CI] [0.33-0.95], p = 0.03) and discontinuation due to patients' elective choice (HR = 0.41, 95% CI [0.21-0.80], p = 0.009) were significantly associated with a lower risk of relapse. Re-treatment with vedolizumab was noted in 24 patients and provided steroid-free clinical remission in 71% and 62.5% at Week 14 and after a median follow-up of 11.0 [5.4-13.3] months, respectively, without any infusion reactions.


CONCLUSIONS
In this retrospective study, two-thirds of patients with IBD treated with vedolizumab experienced relapse within the first year after vedolizumab discontinuation. Re-treatment with vedolizumab was effective in two-thirds of patients.
['Martin|Antoine|A|', 'Nachury|Maria|M|', 'Peyrin-Biroulet|Laurent|L|', 'Bouhnik|Yoram|Y|', 'Nancey|Stephane|S|', 'Bourrier|Anne|A|', 'Serrero|Melanie|M|', 'Fumery|Mathurin|M|', 'Buisson|Anthony|A|', 'Laharie|David|D|', 'Gilletta|Cyrielle|C|', 'Filippi|Jerome|J|', 'Allez|Matthieu|M|', 'Bouguen|Guillaume|G|', 'Roblin|Xavier|X|', 'Altwegg|Romain|R|', 'Dib|Nina|N|', 'Pineton de Chambrun|Guillaume|G|', 'Savoye|Guillaume|G|', 'Carbonnel|Franck|F|', 'Viennot|Stephanie|S|', 'Amiot|Aurelien|A|', '|||']
D000328:Adult D061067:Antibodies, Monoclonal, Humanized D002097:C-Reactive Protein D003093:Colitis, Ulcerative D003424:Crohn Disease D000069340:Deprescriptions D005260:Female D005500:Follow-Up Studies D005765:Gastrointestinal Agents D006801:Humans D008297:Male D057240:Patient Preference D012008:Recurrence D012074:Remission Induction D019233:Retreatment D012189:Retrospective Studies
inflammatory bowel disease vedolizumab Crohn’s disease ulcerative colitis